JPH04506066A - 脈管形成を抑制するためのスラミン・タイプの化合物および脈管形成抑止ステロイド類 - Google Patents

脈管形成を抑制するためのスラミン・タイプの化合物および脈管形成抑止ステロイド類

Info

Publication number
JPH04506066A
JPH04506066A JP2507619A JP50761990A JPH04506066A JP H04506066 A JPH04506066 A JP H04506066A JP 2507619 A JP2507619 A JP 2507619A JP 50761990 A JP50761990 A JP 50761990A JP H04506066 A JPH04506066 A JP H04506066A
Authority
JP
Japan
Prior art keywords
alkyl
fluoro
hydroxy
dihydroxy
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2507619A
Other languages
English (en)
Japanese (ja)
Inventor
アリストフ，ポール・エイ
ミッチェル，マーク・エイ
ウィルクス，ジョン・ダブリュー
Original Assignee
ジ・アップジョン・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジ・アップジョン・カンパニー filed Critical ジ・アップジョン・カンパニー
Publication of JPH04506066A publication Critical patent/JPH04506066A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP2507619A 1989-06-16 1990-05-17 脈管形成を抑制するためのスラミン・タイプの化合物および脈管形成抑止ステロイド類 Pending JPH04506066A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36693589A 1989-06-16 1989-06-16
US366,935 1989-06-16
US48304490A 1990-02-16 1990-02-16
US483,044 1990-02-16

Publications (1)

Publication Number Publication Date
JPH04506066A true JPH04506066A (ja) 1992-10-22

Family

ID=27003588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2507619A Pending JPH04506066A (ja) 1989-06-16 1990-05-17 脈管形成を抑制するためのスラミン・タイプの化合物および脈管形成抑止ステロイド類

Country Status (4)

Country Link
EP (1) EP0477195A1 (fr)
JP (1) JPH04506066A (fr)
AU (1) AU5640390A (fr)
WO (1) WO1990015816A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991019731A1 (fr) * 1990-06-11 1991-12-26 The Upjohn Company Steroides qui inhibent l'angiogenese
US5972922A (en) * 1990-06-11 1999-10-26 Alcon Laboratories, Inc. Steroids which inhibit angiogenesis
CA2425841C (fr) * 1991-11-22 2006-01-10 Alcon Laboratories, Inc. Steroides angiostatiques
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
GB9225475D0 (en) * 1992-12-05 1993-01-27 Imp Cancer Res Tech Compounds to combat angiogenesis
US5795860A (en) * 1993-03-01 1998-08-18 Repligen Corporation Analogs for specific oligosaccharide-protein interactions and uses therefor
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
FR2736914B1 (fr) * 1995-07-21 1997-08-22 Adir Nouveaux derives d'acide aminophenylphosphonique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IT1276031B1 (it) * 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
WO1997041844A1 (fr) * 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Combinaisons de composes angiostatiques
CA2208916A1 (fr) * 1997-07-03 1999-01-03 Hyal Pharmaceutical Corporation Promotion de la cicatrisation a l'aide de steroides ayant des effets secondaires systemiques reduits comparativement a ceux habituellement associes aux glucocorticoides, aux mineralcorticoides et aux steroides sexuels
US6596703B1 (en) 1997-07-11 2003-07-22 Jagotec Ag Promotion of wound healing utilizing steroids having reduced deteriorous systemic side effects typical of glucocorticoids, mineralocorticoids and sex steroids
CA2339835C (fr) 1998-08-11 2008-12-16 Entremed, Inc. Utilisation de composes oestrogenes en tant qu'agents antifongiques
AUPP609198A0 (en) * 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6759398B2 (en) 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
AR032361A1 (es) 2000-08-05 2003-11-05 Glaxo Group Ltd Derivados de androstano y sales y solvatos de los mismos, su uso para la fabricacion de medicamentos, composiciones farmaceuticas que comprenden tales compuestos, proceso para la preparacion de dichos compuestos, e intermediarios utiles en la preparacion de tales compuestos
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US6995278B2 (en) 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
NZ542059A (en) * 2003-02-28 2009-11-27 Florey Howard Inst Therapeutic compositions comprising an aryl sulphonate such as suramin, for the treatment of a pathological condition or event of the systemic vasculature resulting form the producation of reactive oxygen species.
JP2007529426A (ja) 2004-03-12 2007-10-25 エントレメッド インコーポレイテッド 抗血管新生薬
IL169622A0 (en) * 2005-07-11 2007-07-04 Yeda Res & Dev Methods of screening modulators of interleukin-32 (il-32)modulators of il-32 identified by said methods and their use
WO2007109312A2 (fr) 2006-03-20 2007-09-27 Entremed, Inc. 2-méthoxyestradiol présentant une activité anti-arthritique pouvant modifier l'évolution de la maladie
CA2725008C (fr) 2008-05-28 2017-09-05 Validus Biopharma, Inc. Modulateurs steroidiens non hormonaux de nf-.kappa.b pour le traitement d'une maladie
US9198921B2 (en) 2010-04-05 2015-12-01 Reveragen Biopharma, Inc. Non-hormonal steroid modulators of NF-κB for treatment of disease
CA3206655A1 (fr) 2013-03-29 2014-10-02 Biomed Valley Discoveries, Inc. C. novyi pour le traitement de tumeurs solides chez des etres humains
WO2015191602A2 (fr) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Polythérapies ciblant un stroma associé à une tumeur ou des cellules tumorales
ES2830044T3 (es) 2015-01-30 2021-06-02 Biomed Valley Discoveries Inc Malonato de C21H22C12N4O2 cristalino
NZ772411A (en) 2015-01-30 2022-05-27 Vertex Pharma Crystalline forms of c21h22ci2n4o2
WO2017004205A1 (fr) 2015-06-29 2017-01-05 Reveragen Biopharma, Inc. Modulateurs stéroïdiens non hormonaux de nf-κb pour le traitement de maladies
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3291815A (en) * 1958-12-05 1966-12-13 Pfizer & Co C 6-fluoro-16alpha-methyl corticosteroids
CH628355A5 (de) * 1976-02-24 1982-02-26 Ciba Geigy Ag Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze.
CH634081A5 (en) * 1977-04-13 1983-01-14 Ciba Geigy Ag Process for the preparation of novel androstadiene-17beta-carboxylic acid esters
PT69411A (en) * 1978-04-05 1979-04-01 Syntex Inc 4-halo etianic acids and derivatives thereof
US4607028A (en) * 1983-08-18 1986-08-19 Ciba-Geigy Corporation Novel carboxylic acid esters

Also Published As

Publication number Publication date
AU5640390A (en) 1991-01-08
WO1990015816A1 (fr) 1990-12-27
EP0477195A1 (fr) 1992-04-01

Similar Documents

Publication Publication Date Title
JPH04506066A (ja) 脈管形成を抑制するためのスラミン・タイプの化合物および脈管形成抑止ステロイド類
US3929768A (en) Steroids, processes for their manufacture and preparations containing same
CA2081205C (fr) Steroides inhibant l'angiogenese
JP3333210B2 (ja) 新規プレドニソロン誘導体および該化合物を含有する薬剤
US4265823A (en) Aurothiosteroids
JP2000501732A (ja) 抗炎症薬として有用な新規ステロイドナイトライト／ナイトレートエステル誘導体
HU216636B (hu) Eljárás epesavszármazékok előállítására
JP6549544B2 (ja) ガンおよび他の疾患を治療するための新規化合物
JP2000509072A (ja) 抗炎症剤として有用な新規ステロイド亜硝酸エステルおよび硝酸エステル誘導体
JP2010522732A (ja) 鉱質コルチコイド受容体アンタゴニスト
DK165595B (da) 17-androstancarboxylsyreestere, fremgangsmaade til fremstilling heraf og farmaceutisk praeparat indeholdende samme samt anvendelse af samme til fremstilling af et medikament til behandling af svigtende hjertefunktion
HU183000B (en) Process for preparing corticoid-21-sulphopropionates and salts thereof with pharmaceutical activity
FI57114B (fi) Foerfarande foer framstaellning av nya vid cancerterapi anvaendbara terapeutiskt vaerdefulla enolestrar av steroider
US3254074A (en) Spiroxenones
JPH05194524A (ja) 血栓症および血管痙攣症の治療に有用な７−オキサビシクロヘプチル置換複素環式アミドプロスタグランジン類縁体
JP6356218B2 (ja) 抗腫瘍活性を有する７−α−［９−（４，４，５，５，５−ペンタフルオロペンチルスルフィニル）ノニル］−エストラ−１，３，５（１０）−トリエン−３，１７β−ジオールのエステル誘導体及びその調製方法
JPH02174793A (ja) ３β，１７β―ヒドロキシ―置換ステロイド及び関連するステロイド化合物類
EP0573977A2 (fr) Nouveaux conjugés (estradiol-derivé)-chlorambucil, procédé de leur préparation et les compositions pharmaceutiques
FR2510582A1 (fr) Steroides esterifies en la position 17 et thio-esterifies en la position 21, leur procede de preparation et leur application comme medicament
US20030232797A1 (en) Novel derivatives of androstane and androstene with ascorbic acid and use thereof in treating or preventing various conditions, diseases, and disorders
RU2257391C2 (ru) Производные фузидовой кислоты, стереоизомер, фармацевтические композиции, соединения
US2878157A (en) Sulfur containing steroid compositions
JP3143749B2 (ja) 体重維持または減量を促進するのに有益な△５−アンドロステンおよび治療方法
US3483235A (en) New oestratrienes and process for their manufacture
US3525757A (en) Methods of preparing 15,16beta-methylene-testosterone and esters thereof